How It Works:
The Bioramics Platform
Turning Academic Breakthroughs into Commercial Reality
Bioramics is a purpose-built biotech development platform that transforms early-stage discoveries into acquisition-ready innovations. Here’s how the process works—step by step:
Select and License the Innovation
​​​​
Bioramics identifies high-potential technologies from universities, research institutions, and academic labs.
​
-
We negotiate exclusive IP licenses directly with the university or institution.
​
-
As part of the agreement, the university may receive minority equity in a new subsidiary (Target LLC).
​​
-
Selected interns from the same institution may also be assigned to assist with development.
Form a Target LLC
​
​
For each licensed innovation, Bioramics establishes a dedicated, standalone subsidiary—called a Target LLC—to isolate the technology.
​
-
Each Target LLC is structured with clean ownership, IP protection, and fiduciary controls.
​
-
This entity becomes the sole vehicle through which development and eventual commercialization take place.
​
-
Universities or partners may also hold equity stakes in these entities, if agreed.
Align Funding from Donors, Sponsors, and Investors
Capital is secured to fund development through targeted outreach to donors, philanthropic foundations, corporate sponsors, government grants, and institutional or private investors.
​
-
Each funder can select which innovation(s) to support.
​​
-
Funds are directed through Bioramics and allocated to the corresponding Target LLC.
Execute Development via SciRegenix
The Target LLC then contracts with SciRegenix, Bioramics' wholly owned operational subsidiary, via a Master Services Agreement (MSA).
​
-
SciRegenix provides expert-led execution, including scientific de-risking, regulatory strategy, CRO management, preclinical data generation, and commercial preparation.
​​
-
Interns and professionals are assigned to work on that specific Target LLC, driving value and progress.
De-Risk, Validate, and Grow Valuation
With expert support from SciRegenix, the innovation progresses through key development milestones.
​
-
Data is validated, IP is strengthened, and regulatory and scientific hurdles are addressed.
​
-
SciRegenix constantly adjusts resources to optimize progress and increase the asset’s valuation.
​
-
The goal is to close the "Valley of Death" by professionally managing the high-risk middle phase of commercialization.
Sell to Strategic Buyer
(Big Pharma)
Once sufficiently de-risked and validated, the Target LLC is positioned for sale to a strategic buyer—typically a Big Pharma or medical technology company.
​
-
Bioramics facilitates this transaction, transferring the technology into industry hands for global commercialization.
​
-
The sale proceeds flow back through Bioramics to investors, sponsors, and the originating university per the pre-agreed terms.
​
-
Additional royalties and capital gains may continue to flow to the institution over time.
Contact Bioramics
Get in touch to learn more.